168,857 Shares in Nurix Therapeutics, Inc. $NRIX Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, Holdings Channel reports. The institutional investor bought 168,857 shares of the company’s stock, valued at approximately $4,096,000.

Several other hedge funds also recently modified their holdings of NRIX. Larson Financial Group LLC grew its holdings in Nurix Therapeutics by 339.0% during the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after buying an additional 1,190 shares in the last quarter. California State Teachers Retirement System raised its position in Nurix Therapeutics by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock valued at $1,290,000 after buying an additional 1,476 shares during the last quarter. Intesa Sanpaolo Wealth Management bought a new position in Nurix Therapeutics during the 4th quarter valued at $31,000. Royal Bank of Canada lifted its stake in Nurix Therapeutics by 17.6% during the 4th quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock valued at $206,000 after acquiring an additional 1,623 shares in the last quarter. Finally, Arizona State Retirement System boosted its holdings in Nurix Therapeutics by 8.2% during the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock worth $417,000 after acquiring an additional 1,674 shares during the last quarter.

Insider Activity

In other Nurix Therapeutics news, insider Gwenn Hansen sold 1,452 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $25.47, for a total transaction of $36,982.44. Following the completion of the transaction, the insider owned 117,227 shares in the company, valued at $2,985,771.69. This trade represents a 1.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 4,761 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the transaction, the chief financial officer owned 40,166 shares of the company’s stock, valued at $978,443.76. This represents a 10.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 26,766 shares of company stock worth $626,343. Insiders own 6.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Stifel Nicolaus raised their price target on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Robert W. Baird boosted their price target on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Jefferies Financial Group upped their price objective on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Finally, Wall Street Zen upgraded shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.21.

Nurix Therapeutics Trading Up 1.0%

Shares of NASDAQ NRIX opened at $26.04 on Wednesday. The stock has a fifty day simple moving average of $24.65 and a two-hundred day simple moving average of $19.14. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $28.23. The firm has a market cap of $2.70 billion, a price-to-earnings ratio of -7.55 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The firm had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. Analysts forecast that Nurix Therapeutics, Inc. will post -2.73 EPS for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.